DK2257309T3 - Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner - Google Patents

Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner Download PDF

Info

Publication number
DK2257309T3
DK2257309T3 DK09714191.5T DK09714191T DK2257309T3 DK 2257309 T3 DK2257309 T3 DK 2257309T3 DK 09714191 T DK09714191 T DK 09714191T DK 2257309 T3 DK2257309 T3 DK 2257309T3
Authority
DK
Denmark
Prior art keywords
bactery
chlorophyl
rgd
diagnosis
conjugates used
Prior art date
Application number
DK09714191.5T
Other languages
English (en)
Inventor
Avigdor Scherz
Liat Goldshaid
Yoram Salomon
Original Assignee
Yeda Res And Development Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res And Development Company Ltd filed Critical Yeda Res And Development Company Ltd
Application granted granted Critical
Publication of DK2257309T3 publication Critical patent/DK2257309T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036Porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0451Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
DK09714191.5T 2008-02-27 2009-03-01 Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner DK2257309T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6429808P 2008-02-27 2008-02-27
PCT/IL2009/000228 WO2009107139A1 (en) 2008-02-27 2009-03-01 Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors

Publications (1)

Publication Number Publication Date
DK2257309T3 true DK2257309T3 (da) 2020-01-20

Family

ID=40677556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09714191.5T DK2257309T3 (da) 2008-02-27 2009-03-01 Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner

Country Status (15)

Country Link
US (1) US8815213B2 (da)
EP (2) EP2712627A3 (da)
JP (1) JP5620279B2 (da)
KR (1) KR101595138B1 (da)
CN (1) CN102036684B (da)
AU (1) AU2009219682B2 (da)
BR (1) BRPI0907791A2 (da)
CA (1) CA2717060C (da)
DK (1) DK2257309T3 (da)
ES (1) ES2764781T3 (da)
MX (1) MX2010009530A (da)
PT (1) PT2257309T (da)
RU (1) RU2518296C2 (da)
WO (1) WO2009107139A1 (da)
ZA (1) ZA201006789B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331910B2 (en) * 2005-12-16 2012-11-29 Amit Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
KR101253709B1 (ko) * 2011-06-02 2013-04-12 경북대학교 산학협력단 분비형 표적 추적 융합 단백질
AU2012305327B2 (en) 2011-09-05 2016-07-14 Hiroshi Maeda Polymer-type fluorescent molecule probe
JP6106259B2 (ja) * 2012-03-21 2017-03-29 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 医用イメージングと生検データとを統合する臨床ワークステーション及びこれを使用する方法
CN103705532B (zh) * 2012-10-08 2016-09-14 浙江海正药业股份有限公司 靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途
CA2950299A1 (en) * 2014-06-02 2015-12-10 Li-Cor, Inc. Phthalocyanine probes and uses thereof
US10830678B2 (en) 2014-08-08 2020-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Photo-controlled removal of targets in vitro and in vivo
US10441668B2 (en) 2014-12-08 2019-10-15 University Health Network System and method for enhanced mass spectrometry imaging
US10682427B2 (en) 2014-12-19 2020-06-16 Bracco Imaging S.P.A. Intra-operative imaging
EP3166606B1 (en) * 2015-06-03 2018-05-09 Surgimab S.A.S. Fluorescent conjugates
WO2017049403A1 (en) 2015-09-22 2017-03-30 University Health Network System and method for optimized mass spectrometry analysis
AU2017383008B2 (en) * 2016-12-23 2022-02-17 Bicycletx Limited Peptide ligands for binding to MT1-MMP
CN110603261A (zh) * 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
WO2019032683A2 (en) * 2017-08-08 2019-02-14 Board Of Trustees Of Michigan State University LIGHT-EMITTING ORGANIC SALTS FOR ENHANCED PHOTODYNAMIC THERAPY AND IMAGING
JP6920931B2 (ja) * 2017-09-01 2021-08-18 富士フイルム株式会社 医療画像処理装置、内視鏡装置、診断支援装置、及び、医療業務支援装置
RU2700407C1 (ru) * 2018-07-23 2019-09-16 Михаил Тимофеевич Александров Способ лечения опухолевых и воспалительных заболеваний с применением фотодинамической терапии
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
CN112933252A (zh) * 2021-01-28 2021-06-11 厦门大学附属翔安医院 一种乳腺癌特异靶向分子探针及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121876A1 (de) 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
AU3141693A (en) 1991-11-22 1993-06-15 Friedman, Mark M. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US6147195A (en) 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE19756773A1 (de) * 1997-12-19 1999-06-24 Dade Behring Marburg Gmbh Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik
PT1137411E (pt) 1998-12-09 2007-02-28 Yeda Res & Dev Processo para inibir respostas ao etileno em plantas
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
US7045117B2 (en) 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
NZ551845A (en) 2004-06-07 2010-08-27 Yeda Res & Dev Cationic bacteriochlorophyll derivatives and uses thereof
AU2007244705A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
ES2763237T3 (es) * 2006-08-23 2020-05-27 Yeda Res & Dev Conjugados de péptidos de RGD y fotosensibilizantes de (bacterio)clorofila y sus usos
WO2009038660A1 (en) * 2007-09-14 2009-03-26 Health Research, Inc. Multimodality agents for tumor imaging and therapy

Also Published As

Publication number Publication date
CA2717060A1 (en) 2009-09-03
EP2257309B1 (en) 2019-10-16
KR20100127798A (ko) 2010-12-06
MX2010009530A (es) 2010-11-30
JP2011513298A (ja) 2011-04-28
US20110064658A1 (en) 2011-03-17
ZA201006789B (en) 2012-01-25
WO2009107139A1 (en) 2009-09-03
AU2009219682B2 (en) 2015-06-18
KR101595138B1 (ko) 2016-02-18
ES2764781T3 (es) 2020-06-04
PT2257309T (pt) 2020-01-22
RU2518296C2 (ru) 2014-06-10
CN102036684A (zh) 2011-04-27
US8815213B2 (en) 2014-08-26
CN102036684B (zh) 2017-06-09
EP2712627A2 (en) 2014-04-02
EP2712627A3 (en) 2014-04-16
RU2010139461A (ru) 2012-04-10
EP2257309A1 (en) 2010-12-08
CA2717060C (en) 2016-11-01
BRPI0907791A2 (pt) 2015-08-04
AU2009219682A1 (en) 2009-09-03
JP5620279B2 (ja) 2014-11-05

Similar Documents

Publication Publication Date Title
DK2257309T3 (da) Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner
FR2935252B1 (fr) Instrument pour endoscope.
BRPI0916721A2 (pt) endoscópio de prisma giratório
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
DK3056214T3 (da) Hidtil ukendte adjuvanssammensætninger
BRPI0911101A2 (pt) cápsula endoscópica
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
DK2139494T3 (da) Farmaceutiske formuleringer, der indeholder dapagliflozin-propylenglycolhydrat
BRPI0917148A2 (pt) anticorpos anti-cd5
FI20095006A (fi) Kompaktit monimuuntajat
BRPI0920648A2 (pt) Combinações pesticidas contendo sulfoxaflor
BRPI0911849A2 (pt) protetores solares
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
FR2939039B1 (fr) Nouvel agent inhibiteur de secretion de sebum
BRPI0811604A2 (pt) Dispositivo de acesso tipo bolsa universal livre de agulha
BRPI0921997A2 (pt) dispositivo para medição do componente de sangue.
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI1012156A2 (pt) instrumento endoscópico.
BRPI0907448A2 (pt) Instrumentos.
BRPI0923583A2 (pt) síntese de conjugados de polímeros de compostos de indocarbzol.
DK2245463T3 (da) Diagnostisk fremgangsmåde
BRPI0915176A2 (pt) acoplador
DE602007002604D1 (de) Einwegkompatibilitätsverschlüsselung für feste Tintenstifte
BRPI0914065A2 (pt) acoplamento de bloqueio
BRPI0906846A2 (pt) Beta-lactamas terapêuticas.